NovaQuest’s partners have found an interesting way to invest in pharmaceuticals at a time when neither the focus on healthcare nor the potential for treatment of rare diseases have been greater.
“We are investing in the late stages of R&D and commercialization of pharmaceutical products,” said Jonathan Tunnicliffe, the founding partner and chief investment officer of NovaQuest Capital Management.
We're not trying to underwrite the science. We're looking to interpret the data.
The investment firm was founded as part of Quintiles, now known as . . .
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available. Research articles require an Annual sub.